SCHEMBL3973481

SCHEMBL3973481

Cc1cc(N2CCN(C3CCCC3)CC2)nnc1-c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
HRH3 Q9Y5N1 8/20 0.44
KDM2B Q8NHM5 2/20 0.41
CYP11B2 P19099 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
SCN5A Q14524 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
CCR4 P51679 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971714 0.79 KMT2A (0.40) HRH3KMT2AMEN1ALDH1A1MAPK14
SCHEMBL3967998 0.77 MAPT (0.51) HRH3KDM2BCYP11B2KMT2AMEN1
SCHEMBL14544933 0.75 CKS1B (0.49) HRH3KDM2BCYP11B2
SCHEMBL16217074 0.69 KMT2A (0.67) HRH3KMT2AMEN1ALDH1A1MAPK1
SCHEMBL9310546 0.69 CYP1A2 (0.65) HRH3KMT2AMEN1ALDH1A1LMNA
SCHEMBL10349621 0.69 KDM4E (0.54) GAAKMT2AMEN1ALDH1A1MAPK1
SCHEMBL1753087 0.68 MAPK14 (0.67) HRH3KMT2AMEN1ALDH1A1MAPK11
SCHEMBL1753003 0.68 MAPK14 (0.67) HRH3KMT2AMEN1ALDH1A1MAPK11
SCHEMBL2780491 0.68 KMT2A (0.65) HRH3KMT2AMEN1ALDH1A1MAPK1
SCHEMBL22848099 0.68 KMT2A (0.65) HRH3KMT2AMEN1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101805298-A Novel aryl-with heteroaryl-piperazine HIGH POINT PHARMACEUTICALS LLC 2010-08-18 CN claimed
CN-101805298-A Novel aryl-with heteroaryl-piperazine HIGH POINT PHARMACEUTICALS LLC 2010-08-18 CN disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
CN-1628109-A Novel aryl-and heteroaryl-piperazines NOVO NORDISK AS (DK) 2005-06-15 CN disclosed
EP-1474401-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 US disclosed
WO-2003066604-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 GAA 2437/4885ALOX15 1092/4885HRH3 1/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 GAA 2437/4885ALOX15 1092/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.